Navigation Links
Ophthotech Enrolls Its First Patient in a Randomized, Controlled Phase II Study of E10030 in Macular Degeneration
Date:4/26/2010

PRINCETON, N.J., April 26 /PRNewswire/ -- Ophthotech Corp. ("Ophthotech"), a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, today announced that the first patient has been enrolled in its Phase II randomized, controlled clinical trial of E10030, an anti-PDGF aptamer, in combination with Lucentis® for the treatment of wet age-related macular degeneration (AMD).  

The Phase II trial will assess the efficacy and safety of the combination treatment regimen with approximately 444 patients enrolled at sites in the U.S., Europe and Latin America. In a Phase I clinical study, 59 percent of patients treated with E10030 and Lucentis, an anti-VEGF agent, gained significant vision (3-line gain or better) 12 weeks after the start of therapy.  Notably, there was a mean decrease of 86% in the area of choroidal neovascularization (CNV) at 12 weeks.  In comparison, current standard of care utilizing monotherapy anti-VEGF treatment does not induce significant neovascular regression and results in 3-line or better visual gain in approximately one third of patients.

"With current standard of care, the majority of wet AMD patients do not achieve significant visual gain nor neovascular regression," said Samir Patel, MD, president and CEO of Ophthotech. "Combination therapy with E10030 demonstrates a significant advancement in the treatment of wet AMD.  The magnitude of neovascular regression noted in this Phase 1 study appears to be associated with a significant visual gain in the majority of these patients after only 12 weeks, a result not seen with anti-VEGF treatment alone."

Wet AMD is characterized by the
'/>"/>

SOURCE Ophthotech Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
2. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
3. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
4. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
5. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
6. Transdel Enrolls First Patient for Ketotransdel(TM) Phase 3 Clinical Trial
7. Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial
8. HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study
9. S.C. Medical Home Pilot for Diabetes Enrolls 1,110
10. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
11. Facet Solutions Enrolls 100th Patient in US Pivotal IDE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015  Landauer, Inc. (NYSE: ... environmental radiation measurement and monitoring, outsourced medical physics services ... will release financial results for the fiscal third quarter ... 2015. The Company will also host ... 2015 at 9:00 a.m. Central Time (10:00 a.m. Eastern ...
(Date:8/3/2015)... Calif., Aug. 3, 2015 AcelRx Pharmaceuticals, Inc. ... on the development and commercialization of innovative therapies for ... update and reported financial results for the three and ... highlights include: , On July 23, 2015, the ... a positive opinion for Zalviso™ for the management of ...
(Date:8/3/2015)... 3, 2015  LEO Pharma supports the recent decision ... include psoriasis as one of eight priority disease areas ... .  Psoriasis is an autoimmune disease that has a ... 7.5 million people in the US alone. ii ... to supporting patients living with psoriasis, LEO Pharma along ...
Breaking Medicine Technology:Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 2LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 3
... India, Oct. 19 Cardiac Science Corporation (Nasdaq: ... NSE: OPTOCIRCUI] today announced they have entered into a definitive ... all of the outstanding shares of Cardiac Science common stock ... 10% premium to the closing price of Cardiac Science common ...
... 18 Althea Technologies, Inc., a leading provider ... parenteral drug products, announced today that it has ... high-speed syringe filling line.  This line is located ... in San Diego. The expanded capacity complements existing ...
Cached Medicine Technology:Opto Circuits to Acquire Cardiac Science 2Opto Circuits to Acquire Cardiac Science 3Opto Circuits to Acquire Cardiac Science 4Opto Circuits to Acquire Cardiac Science 5Opto Circuits to Acquire Cardiac Science 6Opto Circuits to Acquire Cardiac Science 7Althea Technologies Announces the Installation of a High-Speed Prefilled Syringe Line 2
(Date:8/3/2015)... , ... August 03, 2015 , ... ... ALS and amputation , AUGUST 3, 2015 – Since winning a South by ... 2015, Not Impossible – an organization whose mission is to develop technology for ...
(Date:8/3/2015)... ... 2015 , ... The art of preparing and cooking food comes naturally to ... young age, Nasreen Zereshki was extremely eager to cook Persian cuisine. Now that she ... My Persian Kitchen with the world. , Since Americans tend to be undereducated about ...
(Date:8/3/2015)... ... 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing ... Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker Meridien ... Company’s presentation may be accessed via the investor relations section of the Company’s website. ...
(Date:8/3/2015)... OR (PRWEB) , ... August 03, 2015 , ... ... California’s Modoc National Forest, to Ahjumawi Lava Springs, California’s northernmost and among its ... California’s largest untapped ground water aquifers, whose main outflow is at Ahjumawi Lava ...
(Date:8/3/2015)... ... 2015 , ... A July 9 article from USA Today has ... to the American Dental Association. According to a study by the American Dental Association, ... in a single year to 2.2 million a year. Dentists and ADA officials all ...
Breaking Medicine News(10 mins):Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3
... Introduces New Educational ... Resource at IDSA Annual Meeting, HADDON HEIGHTS, ... a new continuing education,resource as part of their exhibit booth ... America (IDSA), October 4-7, in San Diego,California. Project CDAD: Outbreak ...
... reveal new ways of controlling and treating breast cancer ... today (Monday 1 October 2007). , Dr Robert Clarke ... group have been investigating human breast cancers for the ... tumours and can cause the cancer to recur - ...
... CHICAGO, Oct. 1 Y-ME Illinois will host a ... and,friends. The BIG Night Out - Indulgence for ... 6:30 p.m. to 10:00 p.m. in the Great Hall ... pamper themselves by,partaking in indulgences such as onsite spa ...
... Oct. 1 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals,Corp. today ... signed amended,agreements with Smith & Nephew wound ... dressings with SILCRYST(TM) nanocrystalline coatings.,The two companies ... when Smith &,Nephew bought the Acticoat(TM) brand ...
... WINDSOR, Conn., Oct. 1 UTC Power, a,United ... announced it has,acquired Dome- Tech Group, a national ... New York City. Financial terms were not disclosed. ... energy costs,and improve overall efficiency. It facilitates green, ...
... Achieve Optimum Health, SOMERSET, N.J., Oct. 1 ... announced that it has launched a fourth business,segment, ... pharmaceutical,companies and healthcare payors achieve the best possible ... and stay on the right therapy, everyone wins ...
Cached Medicine News:Health News:National Experts Team Up to Help Hospitals Prevent and Control C. difficile Outbreaks 2Health News:Manchester researchers announce new methods of beating breast cancer 2Health News:Y-ME Illinois Hosts the First-Ever 'BIG Night Out' - Indulgence for a Cause 2Health News:NUCRYST and Smith & Nephew Revise Agreements 2Health News:NUCRYST and Smith & Nephew Revise Agreements 3Health News:NUCRYST and Smith & Nephew Revise Agreements 4Health News:NUCRYST and Smith & Nephew Revise Agreements 5Health News:NUCRYST and Smith & Nephew Revise Agreements 6Health News:NUCRYST and Smith & Nephew Revise Agreements 7Health News:UTC Power Acquires Dome-Tech Group 2Health News:inVentiv Health Launches Fourth Business Segment: inVentiv Patient Outcomes 2Health News:inVentiv Health Launches Fourth Business Segment: inVentiv Patient Outcomes 3
... Test is an immunochromatography based ... is designed for qualitative determination ... The presence of myoglobin in,serum ... higher can be detected in ...
... test kit is an immunochromatographic in vitro ... immunoglobulin E in human serum or plasma. ... with allergic pathologies. It may also be ... Rapid detection of IgE using InstaTest IgE ...
... physiological monitor offers a comprehensive array of ... for pediatric and neonate patients, to magnetic ... Veris is the first MR monitor designed ... and neonate patient monitoring. The new monitor ...
... AFP is an immunochromatographic in vitro assay ... in human serum. AFP is a protein ... 74,000 D. Its normal concentration in serum ... associated with hepatoma and ovarian, testicular and ...
Medicine Products: